At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, our vision is not just to shrink tumors but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. We will work tirelessly to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2011
Size (employees)
118 (est)+3%
Website
ignyta.com
Ignyta was founded in 2011 and is headquartered in San Diego, US

Ignyta Office Locations

Ignyta has an office in San Diego
San Diego, US (HQ)
11095 Flintkote Ave

Ignyta Financials and Metrics

Ignyta Financials

Ignyta's revenue was reported to be $150 k in FY, 2014
USD

Net income (Q2, 2017)

(28.3 m)

EBIT (Q2, 2017)

(27.7 m)

Market capitalization (13-Dec-2017)

897.3 m

Cash (31-Dec-2016)

24.3 m
Ignyta's current market capitalization is $897.3 m.
USDY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150 k

Revenue growth, %

(100%)

EBIT

(13.9 m)

Interest expense

203.8 k
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

150 k

R&D expense

8.8 m10.4 m19.8 m20 m16.6 m34 m22.2 m

General and administrative expense

3.9 m3.9 m5.2 m5.5 m6.1 m5.6 m5.5 m

Operating expense total

12.7 m14.3 m25 m25.5 m22.8 m39.6 m27.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

51.8 m6.3 m46.4 m24.3 m

Inventories

1.7 m4.4 m

Current Assets

52.5 m71.3 m136.2 m111.9 m

PP&E

18.8 m6.3 m
USDQ1, 2014

Cash

52.6 m

Current Assets

78.9 m

Total Assets

102.1 m

Accounts Payable

1.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.2 m)(40 m)(92.5 m)(103.6 m)

Depreciation and Amortization

112.4 k527.7 k

Inventories

(800.7 k)

Accounts Payable

2.9 m95 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(79.4 k)(13.1 m)(14.6 m)(25.5 m)(26.7 m)(23.3 m)(40.2 m)

Accounts Payable

2 m797.9 k1.8 m1.8 m3.2 m8.8 m1.7 m2.1 m
Show all financial metrics

Ignyta Market Value History

Ignyta's Web-traffic and Trends

Ignyta Online and Social Media Presence

Ignyta Company Life and Culture

You may also be interested in